S. Swallow

发表

Fluorine in medicinal chemistry.

S. Purser, Peter R. Moore, S. Swallow, 2008, Chemical Society reviews.

In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.

Yan Li, Hugues Dolgos, R. A. Thompson, 2012, Chemical research in toxicology.

Fluorine-Containing Pharmaceuticals

S. Swallow, 2012 .

Cycloaddition approaches to oxygen heterocycles applied to natural product synthesis

L. Harwood, S. Swallow, J. Robertson, 1999 .

Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479.

Wen Jiang, R. Devos, J. Symons, 2007, Bioorganic & medicinal chemistry letters.

Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors.

J. E. Robinson, J. Blake, S. Le Pogam, 2009, Bioorganic & medicinal chemistry letters.

Pharmacological and electrophysiological characterisation of hERG activator AZSMO-23 1 Running title : Characterisation of hERG activator AZSMO-23

N. Abi-Gerges, M. Bridgland-Taylor, S. Swallow, 2015 .

Aortic Binding of AZD5248: Mechanistic Insight and Reactivity Assays To Support Lead Optimzation.

P. Macfaul, J. Tugwood, S. Swallow, 2015, Chemical research in toxicology.

The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4'-azidocytidine against hepatitis C virus replication: the discovery of 4'-azido-2'-deoxy-2'-fluorocytidine and 4'-azido-2'-dideoxy-2',2'-difluorocytidine.

K. Benkestock, N. Cammack, S. Le Pogam, 2009, Journal of medicinal chemistry.

Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.

Y. Li, W. Huber, T. Mirzadegan, 2008, Bioorganic & medicinal chemistry letters.

Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase.

Yu Li, Andrew Briggs, Klaus Klumpp, 2008, Bioorganic & medicinal chemistry letters.

Fluorine in medicinal chemistry.

S. Swallow, Steve Swallow, 2015, Progress in medicinal chemistry.

Electrophilic Amination of Carbanions by N‐Carboxamido Oxaziridines.

A. Armstrong, S. Swallow, Mark A. Atkin, 2000 .

Electrophilic amination of carbanions by N-carboxamido oxaziridines

A. Armstrong, S. Swallow, Mark A. Atkin, 2000 .

Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).

S. Connolly, S. Swallow, H. Käck, 2016, Journal of medicinal chemistry.

Enantioselective propargylic oxidation

Mark S. Taylor, J. S. Clark, S. Swallow, 1998 .

Stereoselective Synthesis of cis-2,5-Disubstituted Tetrahydrofurans Using Oxabicyclo[3.2.1]heptanone Platforms. Building Blocks for Natural Product Synthesis

G. Molander, S. Swallow, 1994 .

Enantioselective synthesis of homoallylic alcohols using(E)-but-2-enyl-trichlorosilane and chiral diamines

R. Angell, A. Barrett, S. Swallow, 1997 .

A concise synthesis of homochiral trans-perhydroazulenes and trans-hydrindanes

D. Jones, S. Swallow, N. Tomkinson, 2001 .

The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine.

K. Benkestock, N. Cammack, S. Le Pogam, 2009, Journal of medicinal chemistry.

Cycloaddition Approaches to Oxygen Heterocycles Applied to Natural Product Synthesis

L. Harwood, S. Swallow, J. Robertson, 1999 .

Asymmetric electrophilic amination of enolates by a chiral N-alkoxycarbonyloxaziridine

A. Armstrong, S. Swallow, Mark A. Atkin, 2001 .

Design and Characterization of R1626, A Prodrug of the HCV Replication Inhibitor R1479 (4′-Azidocytidine) With Enhanced Oral Bioavailability

G. Dore, Xiaoyang Wu, D. Shaw, 2007 .

Short convergent syntheses of 1,11-epithio and 1,11-epoxy steroids

Joseph P. Adams, D. Jones, J. Bowler, 1990 .

Discovery of a potent and selective oral inhibitor of ERK1/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of non-small cell lung cancer (NSCLC).

J. Breed, M. Anderton, Lyman J. L. Feron, 2019, Journal of medicinal chemistry.

Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.

J. Debreczeni, Lyman J. L. Feron, Michael Tonge, 2017, Journal of medicinal chemistry.

The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.

R. Pauptit, S. Gerhardt, D. Brown, 2012, Bioorganic & medicinal chemistry letters.

Stereoselective synthesis of the cyclic ether core of (+)-laurenyne

Claire Wilson, S. Swallow, M. Cacho, 2004 .

A pharma-wide approach to address the genotoxicity prediction of primary aromatic amines

Mick D. Fellows, Robert A. Jolly, Alexander Amberg, 2018, Computational Toxicology.

Stereoselective Synthesis of the Cyclic Ether Core of (+)-Laurenyne.

Claire Wilson, S. Swallow, M. Cacho, 2005 .

Enantioselective allylic acyloxylation catalysed by copper–oxazoline† complexes

S. Swallow, Keith F. Tolhurst, J. Clark, 1998 .

Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules.

Niklas Blomberg, Britt-Marie Swahn, Paul D Leeson, 2011, Bioorganic & medicinal chemistry letters.

Pharmacological and electrophysiological characterization of AZSMO‐23, an activator of the hERG K+ channel

N. Abi-Gerges, M. Bridgland-Taylor, S. Swallow, 2015, British journal of pharmacology.